Hem

Press release from Companies

Publicerat: 2021-02-11 07:45:00

Cessatech A/S: Year-end report Q4-2020 - on track and accelerating clinical activities

Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 6. April – 31 December 2020. The Year-end report is available as an attached document to this press release and on www.cessatech.com under Investor, ‘Filings & Reports’. The company is on track with Q4 activities and getting ready for an exciting year.

Fourth quarter 2020 (1 October – 31 December):

  • Net revenue was KDKK 0 
  • Operating result was KDKK -576 
  • Net result was KDKK -512
  • Cash and bank was KDKK 13,506 
  • Result per share* was DKK -0,16
  • Solidity** was 99%

*Result per share (DKK per share): Operating result divided by the average  number of shares during the period. The total number of shares as of 31 December 2020 amounted to 3,680,000 shares, the average number of shares during the full-year was 1,537,721. There has been an increase in the number of shares since the completion of the IPO in December 2020, the average number of shares for Q4-2020 was 3,255,385 shares.  **Solidity: Total equity divided by total capital and liability

Highlights during Q4-2020

  • Finalized a very successful IPO in December with an oversubscription rate of app 680% 

  • Finalized negotiations of preferred manufacturer for clinical and commercial batches
  • Finalized Registry Study (0203) from 10 years’ data in children from Karolinska University Hospital 
  • Submitted Fast-track US patent application for CT001
  • Initiated clinical preparations of first 3 clinical activities related to CT001
 

"I would like to welcome all new shareholders – and acknowledge you for the strong confidence in our business, our product and us. Together with an extraordinary team, I am looking forward to transforming Cessatech closer to a phase III company - with three (3) major milestones in 2021, the clinical results of 3 studies - 2021 will be a very exciting year" Says Jes Trygved, CEO
 

For more information about Cessatech, please contact:

Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children. CT001 is expected to enter late stage clinical development in 2021.

Läs mer hos Cision
Läs mer om Cessatech A/S

Prenumeration